• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    HilleVax Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/25/25 4:05:28 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HLVX alert in real time by email
    8-K
    false000188801200018880122025-06-232025-06-23

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 23, 2025

     

     

    HILLEVAX, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41365

    85-0545060

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    321 Harrison Avenue

     

    Boston, Massachusetts

     

    02118

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 617 213-5054

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    HLVX

     

    The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒


    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.07.

    Submission of Matters to a Vote of Security Holders.

    On June 23, 2025, HilleVax, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, stockholders voted on the matters disclosed in the Company’s definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on April 30, 2025. The final voting results for the matters submitted to a vote of stockholders were as follows:

    Proposal No. 1 - Election of Class III Directors

    At the Annual Meeting, the Company’s stockholders elected the persons listed below as Class III directors for a three-year term expiring at the Company’s 2028 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified:

     

     

     

     

     

     

     

     

     

     

     

     

    Directors

    Votes For

    Withheld

    Broker Non-Votes

    Robert Hershberg, M.D., Ph.D.

    22,286,355

     

     

     

    1,574,443

     

     

     

    14,522,437

     

    Jeryl Hilleman

    22,039,977

     

     

     

    1,820,821

     

     

     

    14,522,437

     

    Aditya Kohli, Ph.D.

     

    22,355,721

     

     

     

    1,505,077

     

     

     

    14,522,437

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm

    At the Annual Meeting, the Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2025:

     

     

     

     

     

    Votes For

    Votes Against

    Abstentions

    38,241,645

     

    133,485

     

    8,105


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    HilleVax, Inc.

     

     

     

     

    Date:

    June 25, 2025

    By:

    /s/ Paul S. Bavier

     

     

     

    Name: Paul S. Bavier
    Title: General Counsel and Chief Administrative Officer

     


    Get the next $HLVX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HLVX

    DatePrice TargetRatingAnalyst
    7/9/2024$28.00 → $2.00Outperform → Market Perform
    Leerink Partners
    7/9/2024$34.00 → $3.00Buy → Hold
    Stifel
    7/9/2024$28.00 → $2.00Buy → Neutral
    H.C. Wainwright
    7/8/2024Buy → Neutral
    Guggenheim
    7/8/2024$24.00 → $5.00Overweight → Neutral
    JP Morgan
    12/13/2023$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $HLVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Frazier Life Sciences X, L.P. bought $128,325 worth of shares (8,850 units at $14.50) (SEC Form 4)

    4 - HilleVax, Inc. (0001888012) (Issuer)

    4/8/24 4:22:13 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mcloughlin Sean bought $21,225 worth of shares (1,250 units at $16.98) (SEC Form 4)

    4 - HilleVax, Inc. (0001888012) (Issuer)

    4/1/24 4:08:42 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HilleVax downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded HilleVax from Outperform to Market Perform and set a new price target of $2.00 from $28.00 previously

    7/9/24 9:48:14 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax downgraded by Stifel with a new price target

    Stifel downgraded HilleVax from Buy to Hold and set a new price target of $3.00 from $34.00 previously

    7/9/24 7:46:22 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded HilleVax from Buy to Neutral and set a new price target of $2.00 from $28.00 previously

    7/9/24 7:46:01 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HilleVax Reports Second Quarter 2025 Financial Results

    BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2025. Second Quarter Financial Results As of June 30, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and $171.4 million, respectively. Research and development expenses were $3.3 million, compared to $52.6 million for the six months ended June 30, 2025 and 2024. The decrease was primarily due to lower clinical development costs. General and administrative expenses were $11.3 million,

    8/6/25 4:05:00 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

    BOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today they have entered into a definitive merger agreement (the "Merger Agreement"), whereby XOMA Royalty will acquire all of the issued and outstanding common shares of HilleVax.   Under the terms of the Merger Agreement, HilleVax stockholders will receive $1.95 in cash per share of HilleVax common stock at the closing of the merger, plus one non-transferable contingent value right ("CVR"), which represents the right to receive potential payments following the closing of a pro rata portion of:

    8/4/25 7:00:00 AM ET
    $HLVX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

    $159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business development related activities and other strategic alternatives BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2025. First Quarter Financial Results As of March 31, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and

    5/8/25 7:00:30 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    SEC Filings

    View All

    $HLVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form SC 14D9 filed by HilleVax Inc.

    SC 14D9 - HilleVax, Inc. (0001888012) (Subject)

    8/18/25 8:59:03 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC TO-T filed by HilleVax Inc.

    SC TO-T - HilleVax, Inc. (0001888012) (Subject)

    8/18/25 8:23:43 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC14D9C filed by HilleVax Inc.

    SC14D9C - HilleVax, Inc. (0001888012) (Subject)

    8/6/25 4:22:35 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Heron Patrick J was granted 17,199 shares (SEC Form 4)

    4 - HilleVax, Inc. (0001888012) (Issuer)

    6/25/25 5:07:01 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kohli Aditya was granted 17,199 shares, increasing direct ownership by 3% to 698,171 units (SEC Form 4)

    4 - HilleVax, Inc. (0001888012) (Issuer)

    6/25/25 4:55:55 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Chu Shelley was granted 17,199 shares (SEC Form 4)

    4 - HilleVax, Inc. (0001888012) (Issuer)

    6/25/25 4:25:38 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Financials

    Live finance-specific insights

    View All

    HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

    BOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today they have entered into a definitive merger agreement (the "Merger Agreement"), whereby XOMA Royalty will acquire all of the issued and outstanding common shares of HilleVax.   Under the terms of the Merger Agreement, HilleVax stockholders will receive $1.95 in cash per share of HilleVax common stock at the closing of the merger, plus one non-transferable contingent value right ("CVR"), which represents the right to receive potential payments following the closing of a pro rata portion of:

    8/4/25 7:00:00 AM ET
    $HLVX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series

    BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Fireside chat details:Date:  Tuesday, September 6, 2022Time:  1:00 – 2:00 p.m. Eastern Daylight Time (EDT)Moderator:  Eric Joseph, Ph.D.HilleVax Participant:  Robert Hershberg, M.D., Ph.D.,

    9/1/22 5:18:14 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Leadership Updates

    Live Leadership Updates

    View All

    Frazier Life Sciences Appoints Aditya Kohli to Partner

    Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

    4/17/25 8:00:00 AM ET
    $HLVX
    $PHAT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

    Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "We are excited to remain on track to r

    5/9/24 4:05:00 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

    BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr. McLoughlin's appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy.  Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Le

    1/18/24 7:00:00 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HLVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

    SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

    11/14/24 9:36:33 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

    SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

    11/14/24 9:00:08 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by HilleVax Inc.

    SC 13G - HilleVax, Inc. (0001888012) (Subject)

    7/22/24 9:02:05 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care